AR077483A1 - Sal de citrato del 9e-15-(2-pirrolidin -1-il-etoxi)-7,12,25-trioxa-19-21,24-triaza-tetraciclo (18-3.1.1(2,5).1(14,18) hexacosa-1 (24),2,4,9,14,16,18 (26),20,22- nonaeno - Google Patents

Sal de citrato del 9e-15-(2-pirrolidin -1-il-etoxi)-7,12,25-trioxa-19-21,24-triaza-tetraciclo (18-3.1.1(2,5).1(14,18) hexacosa-1 (24),2,4,9,14,16,18 (26),20,22- nonaeno

Info

Publication number
AR077483A1
AR077483A1 ARP100102594A ARP100102594A AR077483A1 AR 077483 A1 AR077483 A1 AR 077483A1 AR P100102594 A ARP100102594 A AR P100102594A AR P100102594 A ARP100102594 A AR P100102594A AR 077483 A1 AR077483 A1 AR 077483A1
Authority
AR
Argentina
Prior art keywords
citrate salt
nonaeno
hexacosa
trioxa
triaza
Prior art date
Application number
ARP100102594A
Other languages
English (en)
Original Assignee
S Bio Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S Bio Pte Ltd filed Critical S Bio Pte Ltd
Publication of AR077483A1 publication Critical patent/AR077483A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Ciertas sales del 9E-15-(2-pirrolidin-1-iI-etoxi)-7,12,25-trioxa-19,21,24-triaza-tetraciclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,40,9,14,16,18(26),20,22-nonaeno (Compuesto 1) que tienen propiedades mejoradas. En particular, la sal de citrato de este compuesto. Además, composiciones farmacéuticas que contienen la sal de citrato y métodos de uso de la sal de citrato en el tratamiento de trastorno proliferativo. La difraccion de rayos X presenta picos en 2theta a 7,9s+-0,5s; 10,0s+-0,5s; 15,6s+-0,5s; 15,9s+-0,5s; 16,8s+-0,5s; 17,2s+-0,5s, 21,1s+-0,5s; 22,4s+-0,5s.
ARP100102594A 2009-07-15 2010-07-15 Sal de citrato del 9e-15-(2-pirrolidin -1-il-etoxi)-7,12,25-trioxa-19-21,24-triaza-tetraciclo (18-3.1.1(2,5).1(14,18) hexacosa-1 (24),2,4,9,14,16,18 (26),20,22- nonaeno AR077483A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22560909P 2009-07-15 2009-07-15

Publications (1)

Publication Number Publication Date
AR077483A1 true AR077483A1 (es) 2011-08-31

Family

ID=42790728

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP100102594A AR077483A1 (es) 2009-07-15 2010-07-15 Sal de citrato del 9e-15-(2-pirrolidin -1-il-etoxi)-7,12,25-trioxa-19-21,24-triaza-tetraciclo (18-3.1.1(2,5).1(14,18) hexacosa-1 (24),2,4,9,14,16,18 (26),20,22- nonaeno
ARP190102219A AR114987A2 (es) 2009-07-15 2019-08-05 Sal de citrato del 9e-15-(2-pirrolidin-1-il-etoxi)-7,12,25-trioxa-19,21,24-triaza-tetraciclo[18.3.1.1.(2,5).1(14,18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaeno

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP190102219A AR114987A2 (es) 2009-07-15 2019-08-05 Sal de citrato del 9e-15-(2-pirrolidin-1-il-etoxi)-7,12,25-trioxa-19,21,24-triaza-tetraciclo[18.3.1.1.(2,5).1(14,18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaeno

Country Status (19)

Country Link
US (1) US9062074B2 (es)
EP (1) EP2454266B1 (es)
JP (2) JP6013911B2 (es)
CN (1) CN102762577B (es)
AR (2) AR077483A1 (es)
BR (1) BR112012000750B1 (es)
CA (1) CA2768210C (es)
DK (1) DK2454266T3 (es)
ES (1) ES2429525T3 (es)
HK (1) HK1178159A1 (es)
HR (1) HRP20130941T1 (es)
MX (1) MX2012000680A (es)
PL (1) PL2454266T3 (es)
PT (1) PT2454266E (es)
RU (1) RU2543721C2 (es)
SI (1) SI2454266T1 (es)
SM (1) SMT201300112B (es)
TW (1) TWI537276B (es)
WO (1) WO2011008172A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10786461B2 (en) 2014-11-17 2020-09-29 Context Biopharma Inc. Onapristone extended-release compositions and methods
BR112018005999A2 (pt) 2015-09-25 2019-01-08 Context Biopharma Inc métodos para a produção de intermediários de onapristona
KR20180113988A (ko) 2015-12-15 2018-10-17 컨텍스트 바이오파마 인코포레이티드 비정질 오나프리스톤 조성물 및 그 제조방법
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110603A (en) * 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
WO2004078682A2 (en) 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
KR101499594B1 (ko) * 2005-11-16 2015-03-09 씨티아이 바이오파마 코포레이션 산소가 결합된 피리미딘 유도체

Also Published As

Publication number Publication date
TW201107336A (en) 2011-03-01
RU2543721C2 (ru) 2015-03-10
BR112012000750B1 (pt) 2021-05-25
JP2015164941A (ja) 2015-09-17
SI2454266T1 (sl) 2013-10-30
CA2768210C (en) 2017-08-15
MX2012000680A (es) 2012-02-28
TWI537276B (zh) 2016-06-11
AR114987A2 (es) 2020-11-11
DK2454266T3 (da) 2013-09-08
SMT201300112B (it) 2013-11-08
US9062074B2 (en) 2015-06-23
CN102762577B (zh) 2015-01-07
RU2012105044A (ru) 2013-08-20
US20120196876A1 (en) 2012-08-02
JP6013911B2 (ja) 2016-10-25
BR112012000750A2 (pt) 2016-08-09
EP2454266A1 (en) 2012-05-23
CN102762577A (zh) 2012-10-31
PT2454266E (pt) 2013-10-10
ES2429525T3 (es) 2013-11-15
CA2768210A1 (en) 2011-01-20
HRP20130941T1 (hr) 2013-11-08
WO2011008172A1 (en) 2011-01-20
PL2454266T3 (pl) 2014-01-31
HK1178159A1 (en) 2013-09-06
JP2012533539A (ja) 2012-12-27
BR112012000750A8 (pt) 2018-02-06
EP2454266B1 (en) 2013-07-10

Similar Documents

Publication Publication Date Title
ES2649340T3 (es) Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
PH12017501306A1 (en) Inhibitors of histone demethylases
BR112015008365A2 (pt) composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
WO2015095227A3 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
GB201106743D0 (en) Novel compounds
GB201106750D0 (en) Novel compounds
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
AR088694A1 (es) Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
EA201490559A1 (ru) Композиция для лечения свища
AR088622A1 (es) 18-METIL-6,7-METILEN-3-OXO-17-PREGN-4-EN-21,17b-CARBOLACTONA, PREPARADOS FARMACEUTICOS QUE CONTIENEN LOS COMPUESTOS MENCIONADOS Y SU USO EN LA TERAPIA DE LA ENDOMETRIOSIS
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
CL2013001482A1 (es) Compuestos derivados de 3-metil-7-oxo-4-tia-1-aza-biciclo[3.2.0]heptano para utilizarse en la inhibicion de beta-lactamasas producidas por bacterias y restaurar/potenciar la actividad de antibioticos; y composicion farmaceutica que los comprende.
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
CY1117541T1 (el) Αντικαρκινικες στεροειδεις λακτονες μη κορεσμενες στη θεση 7(8)
CL2014001959A1 (es) Compuestos derivados de fenil-1h-imidazo[1,2-b]pirazol sustituidos; procedimiento de preparacion; composicion farmaceutica; y el uso en el tratamiento del cancer.
MX2015015755A (es) Derivados de perhidroquinoxalina utiles como analgesicos.
AR090806A1 (es) Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii
BR112016005317A2 (pt) derivados de quinazolina e seu uso como inibidores de dna metiltransferase
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.
PH12015500185B1 (en) Azaheterocycles as bir2 and/or bir3 inhibitors
AR077483A1 (es) Sal de citrato del 9e-15-(2-pirrolidin -1-il-etoxi)-7,12,25-trioxa-19-21,24-triaza-tetraciclo (18-3.1.1(2,5).1(14,18) hexacosa-1 (24),2,4,9,14,16,18 (26),20,22- nonaeno

Legal Events

Date Code Title Description
FC Refusal